Sepsis & infection

Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis

Ann Intensive CarePublished Systematic review and Bayesian network meta-analysis of randomised trials

Pooled result · 28 day mortalityResult — go to the resultOdds ratio 0.43 95% CrI 0.17–0.94

Authors' conclusion

This network meta-analysis suggests that most antibiotic regimens, including new combinations and cefiderocol, have similar efficacy and safety in treating susceptible Gram-negative bacilli in NP.

Study context

Population
Patients with nosocomial pneumonia (NP) treated with antibiotics targeting Gram-negative bacilli
Participants
4,993 patients · 16 studies
Comparison
13 antibiotic regimens targeting Gram-negative bacilli compared with each other
Outcome
Mortality
Follow-up
28 day

Pooled result

28 day mortality

Odds ratio

0.43

95% CrI 0.17–0.94

Meropenem plus aerosolized colistin vs Intravenous colistin
OR 0.43 (95% CrI 0.17–0.94)

As reported in the abstract

Further pooled results

OutcomeOR (95% CrI)
Clinical failure: ceftazidime vs comparatorsCeftazidime vs Meropenem plus aerosolized colistin · CrI1.97 (1.19–3.45)
Clinical failure: ceftazidime vs comparatorsCeftazidime vs Meropenem · CrI1.40 (1.00–2.01)
Clinical failure: ceftazidime vs comparatorsCeftazidime vs Imipemen/cilastatin/relebactam · CrI1.74 (1.03–2.90)
Clinical failure: ceftazidime vs comparatorsCeftazidime vs Ceftazidime/avibactam · CrI1.48 (1.02–2.20)

Microbiological cure

No substantial difference between regimens; ceftolozane/tazobactam had the highest probability of being superior

Safety

No significant difference between treatments for adverse events
Acute kidney failure more common with intravenous colistin

Original publication

Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis. Ann Intensive Care. Published 25 April 2024. doi:10.1186/s13613-024-01291-5

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.